Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2017
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trialA Bamias, E Gibbs, C Khoon Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Gynecologic Oncology|December 12, 2019
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignanciesI B Vergote, B Lund, U Peen, et al.
Gynecologic Oncology|September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancerI Vergote, A du Bois, A Floquet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent diseaseM K Wilson, E Pujade-Lauraine, D Aoki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 16, 2021
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial<sup>☆</sup>X H Wu, J Q Zhu, R T Yin, et al.
British Journal of Cancer|February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum lineN Colombo, A Gadducci, J Sehouli, et al.
Pageof 3